VHL Antikörper (Internal Region)
-
- Target Alle VHL Antikörper anzeigen
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
-
Bindungsspezifität
- Internal Region
-
Reaktivität
- Human, Maus, Ratte
-
Wirt
- Ziege
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser VHL Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), Immunohistochemistry (IHC), ELISA
- Verwendungszweck
- VHL
- Sequenz
- RSLVKPENYR RLD
- Spezifität
- This antibody is expected to recognise both reported isoforms (NP_000542.1 and NP_937799.1).
- Kreuzreaktivität
- Hund, Human, Maus, Ratte
- Aufreinigung
- Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
- Güteklasse
- Verified
- Immunogen
- Peptide with sequence C-RSLVKPENYRRLD, from the internal region of the protein sequence according to NP_000542.1, NP_937799.1.
- Isotyp
- IgG
- Top Product
- Discover our top product VHL Primärantikörper
-
-
- Applikationshinweise
-
Immunohistochemistry: Paraffin embedded Human Kidney. Recommended concentration: 5 μg/mL.
Western Blot: Approx 17 kDa band observed in Human Ovary and Testis lysates and also in lysates of Mouse and Rat Testis and Brain and of all human and mouse cell lines tested (calculated MW of 19.7 kDa according to NP_937799.1). Recommended concentration:
Peptide ELISA: antibody detection limit dilution 1:128000.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.5 mg/mL
- Buffer
- Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Minimize freezing and thawing.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Aliquot and store at -20°C, with minimal freeze/thawing. A working aliquot may be refrigerated at 4°C for a few weeks and still remain viable.
-
- Target
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Andere Bezeichnung
- VHL (VHL Produkte)
- Synonyme
- HRCA1 antikoerper, RCA1 antikoerper, VHL1 antikoerper, pVHL antikoerper, BcDNA:RH61560 antikoerper, CG13221 antikoerper, DVhl antikoerper, Dmel\\CG13221 antikoerper, Dvhl antikoerper, VHL antikoerper, d-VHL antikoerper, d-vhl antikoerper, dVHL antikoerper, dmVHL antikoerper, vhl antikoerper, rca1 antikoerper, vhl1 antikoerper, hrca1 antikoerper, zgc:158722 antikoerper, Vhlh antikoerper, von Hippel-Lindau tumor suppressor antikoerper, von Hippel-Lindau antikoerper, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase antikoerper, von Hippel-Lindau disease tumor suppressor antikoerper, VHL antikoerper, Vhl antikoerper, vhl antikoerper, CpipJ_CPIJ009992 antikoerper
- Hintergrund
- VHL, von Hippel-Lindau tumor suppressor, HRCA1, RCA1, VHL1 , elongin binding protein, von Hippel-Lindau syndrome
- Gen-ID
- 7428, 22346, 24874
- NCBI Accession
- NP_000542, NP_937799
- Pathways
- Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
-